TrialMolecular cancer2023

REGISTRI: Regorafenib in first-line of KIT/PDGFRA wild type metastatic GIST: a collaborative Spanish (GEIS), Italian (ISG) and French Sarcoma Group (FSG) phase II trial.

Javier Martin-Broto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.